YALE UNIVERSITY
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1701-10-09
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.yale.edu
Blood Glucose Variability and Insulin Action During Menstrual Cycle in Females With Type 1 Diabetes
Not Applicable
Completed
- Conditions
- Type 1 Diabetes
- Interventions
- Device: Follicular Euglycemic clampDevice: Luteal Euglycemic clamp
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Yale University
- Target Recruit Count
- 28
- Registration Number
- NCT02693938
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
Trial Comparing Early Laparoscopic Enterolysis Versus Nonoperative Management for High-grade SBO
Phase 2
Terminated
- Conditions
- Small Bowel Obstruction
- Interventions
- Procedure: Early laparoscopic enterolysisProcedure: nonoperative management
- First Posted Date
- 2016-02-26
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Yale University
- Target Recruit Count
- 3
- Registration Number
- NCT02692638
- Locations
- 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Yale University
- Registration Number
- NCT02686008
Formative Research for an HIV Videogame for Young Black Women
Not Applicable
Completed
- Conditions
- HIV PreventionSTI Prevention
- Interventions
- Other: One Night Stan Prototype
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Yale University
- Target Recruit Count
- 21
- Registration Number
- NCT02685410
- Locations
- 🇺🇸
Yale New Haven Hospital, New haven, Connecticut, United States
Progesterone Augmentation of Nicotine Replacement Therapy Study
Phase 4
Completed
- Conditions
- Smoking Cessation
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Yale University
- Target Recruit Count
- 64
- Registration Number
- NCT02685072
- Locations
- 🇺🇸
Yale School of Medicine, Department of Psychiatry, New Haven, Connecticut, United States
A Mail and Video-based Weight Loss Trial in Breast Cancer Survivors
Not Applicable
Completed
- Conditions
- Breast Cancer SurvivorshipObesity
- Interventions
- Behavioral: LEAN book/videos
- First Posted Date
- 2016-02-15
- Last Posted Date
- 2018-06-29
- Lead Sponsor
- Yale University
- Target Recruit Count
- 205
- Registration Number
- NCT02681965
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer
Phase 2
Active, not recruiting
- Conditions
- Non-small Cell Lung CancerBrain MetastasisMelanoma
- Interventions
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Yale University
- Target Recruit Count
- 42
- Registration Number
- NCT02681549
- Locations
- 🇺🇸
Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- Yale University
- Target Recruit Count
- 33
- Registration Number
- NCT02675530
- Locations
- 🇺🇸
VHA CT, West Haven, Connecticut, United States
Physical Activity and Glycemic Control in Adolescents
Not Applicable
Completed
- Conditions
- Type 1 Diabetes
- Interventions
- Behavioral: Reinforcement for meeting targeted physical activity goalsOther: Standard of Care
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Yale University
- Target Recruit Count
- 12
- Registration Number
- NCT02674828
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion
Not Applicable
Completed
- Conditions
- Type 1 Diabetes
- Interventions
- Other: basal interruption without canagliflozin
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Yale University
- Target Recruit Count
- 10
- Registration Number
- NCT02673138
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
© Copyright 2025. All Rights Reserved by MedPath